Combination strategies with agents like cladribine, azacytidine, and venetoclax further enhance efficacy, even in low-responding cases, highlighting dual STAT3/STAT5 inhibition as a promising therapeutic approach in T-PLL. Here, STAT5B is linked to prolymphocytic leukemia.